Take the challenge; learn the dynamics of business.
Make a real and immediate impact in the pharmaceutical industry and your organisation by applying leading edge tools, and the latest management and leadership thinking.
Ranked 1st in Europe and 3rd in the world*, the Executive MBA at London Business School inspires global business leaders to think critically, plan strategically and act decisively in an interdependent and complex global economy.
Taught by the world's top faculty, you'll gain the analytical skills, understanding and confidence in business language to influence strategy and gain valuable business insights to the dynamics of the pharmaceutical industry.
The diversity of students in terms of nationalities, industries and cultures not only broadens your perspective and enhances class debate, but also provides you access to an extensive and international network of professionals. This powerful combination can be applied to crafting the success of your organisation and future career.
Studying on alternate Fridays and Saturdays enables you to pursue your studies without interrupting your career momentum. We offer an extensive range of elective courses to meet your areas of interest and specialisation. The International Assignments are specifically designed so you can effectively manage and communicate across boundaries.
Accelerate your career today with the Executive MBA. To speak to our current students and alumni, and experience a taste of our world-class faculty come to our next information sessions on Tuesday 20th June and Tuesday 18 July. Or look online at http://www.london.edu/epe
*Financial Times survey, 2005
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.